Tiny study aims to unlock timing secrets of embryo implantation
NCT ID NCT07028710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study looks at how progesterone levels change after using a hormone shot (hCG) to trigger ovulation in women preparing for frozen embryo transfer. Forty women will give blood samples over six days to track their hormone patterns. The goal is to learn if hCG affects the timing of the luteal phase, which may help improve embryo implantation success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * At least 1 follicle of 14 mm or more * Endometrium of 6 mm or more * Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng/mL * For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care). Exclusion Criteria: * Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period. * Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion. * Patient who has not given written consent to participate in the study. * Patient not fluent in French. * Patient under guardianship, curators or without social security coverage. * Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Luteal phase insufficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Arnaud de Villeneuve
RECRUITINGMontpellier, 34000, France